Finasteride induces apoptosis via Bcl-2, Bcl-xL, Bax and caspase-3 proteins in LNCaP human prostate cancer cell line

International Journal of Oncology

Volumn 32, Issue 4, 2008, Pages 919-924

  Golbano, Jesús M ^a   López Aparicio, Pilar ^b   Recio, María N ^b   Pérez Albarsanz, Miguel A ^b  

^a HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^b UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

Apoptosis; Bax; Bcl 2; Bcl xL; Caspase 3; Finasteride; LNCaP cells; Prostate cancer

Indexed keywords

CASPASE 3; FINASTERIDE; PROCASPASE 3; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; STEROID 5ALPHA REDUCTASE INHIBITOR; CHOLESTENONE 5ALPHA REDUCTASE; ENZYME INHIBITOR; PROTEIN BCL X;

APOPTOSIS; ARTICLE; CELL DEATH; CELL STRAIN LNCAP; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOREACTIVITY; INCUBATION TIME; MALE; MITOCHONDRION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FAMILY; WESTERN BLOTTING; DRUG ANTAGONISM; DRUG EFFECT; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; CASPASE 3; CELL LINE, TUMOR; CHOLESTENONE 5 ALPHA-REDUCTASE; ENZYME INHIBITORS; FINASTERIDE; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 44449178895     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.32.4.919     Document Type: Article

References (36)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 57: 43-66, 2007.
2. Boring CC, Squires TS, Tong T and Montgomery S: Cancer statistics, 1994. CA Cancer J Clin 44: 7-26, 1994.
3. Sternberg CN: What's new in the treatment of advanced prostate cancer? Eur J Cancer 39: 136-146, 2003.
4. Aumuller G: Morphologic and regulatory aspects of prostatic function. Anat Embryol 179: 519-531, 1989.
5. Zhu YS: Molecular basis of steroid action in the prostate. Cell Science 1: 27-55, 2005.
6. Finn DA, Beadles-Bohling AS, Beckley EH, Ford MM, Gililland KR, Gorin-Meyer RE and Wiren KM: A new look at the 5alpha-reductase inhibitor finasteride. CNS Drug Rev 12: 53-76, 2006.
7. Rittmaster RS: 5alpha-reductase inhibitors. J Androl 18: 582-587, 1997.
8. Titus MA, Gregory CW, Ford OH, Schell MJ, Maygarden SJ and Mohler JL: Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res 11: 4365-4371, 2005.
9. Fleshner NE and Trachtenberg J: Combination finasteride and flutamide in advanced carcinoma of the prostate: effective therapy with minimal side effects. J Urol 154: 1642-1645, 1995.
10. Russell DW and Wilson JD: Steroid 5 alpha-reductase: two genes/two enzymes. Annu Rev Biochern 63: 25-61, 1994.
11. Steers WD: 5α-reductase activity in the prostate. Urology 58: 17-24, 2001.
12. Bologna M, Muzi P, Biordi L, Festuccia C and Vicentini C: Finasteride dose-dependently reduces the proliferation rate of the LNCaP human prostatic cancer cell line in vitro. Urology 45: 282-290, 1995.
13. Rittmaster RS, Manning AP, Wright AS Thomas LN, Whitefield S, Norman RW, Lazier CB and Rowden G: Evidence for atrophy and apoptosis in the ventral prostate of rats given the 5α-reductase inhibitor finasteride. Endocrinology 136: 741-748, 1995.
14. Zhu YS, Cai LQ, You X, Cordero JJ, Huang Y and Imperato-McGinley J: Androgen-induced prostate-specific antigen gene expression is mediated via dihydrotestosterone in LNCaP cells. J Androl 24: 681-687, 2003.
15. Westin P, Stattin P, Damber JE and Bergh A: Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors. Am J Pathol 146: 1368-1375, 1995.
16. Strasser A, O'Connor L and Dixit VM: Apoptosis signaling. Annu Rev Biochem 69: 217-245, 2000.
17. Baliga BC and Kumar S: Role of Bcl-2 family of proteins in malignancy. Hematol Oncol 20: 63-74, 2002.
18. Hockenbery D, Nunez G, Milliman C, Schreiber RD and Korsmeyer SJ: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348: 334-336, 1990.
19. Hickman JA: Apoptosis induced by anticancer drugs. Cancer Metastasis Rev 11: 121-139, 1992.
20. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand, EA and Murphy GP: LNCaP model of human prostatic carcinoma. Cancer Res 43: 1809-1818, 1983.
21. Schuurmans AL, Bolt J and Mulder E: Androgens stimulate both growth rate and epidermal growth factor receptor activity of the human prostate tumor cell LNCaP. Prostate 12: 55-63, 1988.
22. Trapani G, Dazzi L, Pisu MG, Reho A, Seu E and Biggio G: A rapid method for obtaining finasteride, a 5α-reductase inhibitor, from commercial tablets. Brain Res Protocols 9: 130-134, 2002.
23. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685, 1970.
24. Towbin H, Stachelin T and Gordon J: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose: procedure and some applications. Proc Natl Acad Sci USA 76: 4350-4353, 1979.
25. Saraste A and Pulkki K: Morphologic and biochemical hallmarks of apoptosis. Cardiovasc Res 45: 528-537, 2000.
26. Nicotera P: Caspase requirement for neuronal apoptosis and neurodegeneration. IUBMB Life 49: 421-425, 2000.
27. Lazier CB, Thomas LN, Douglas RC, Vessey JP and Rittmaster RS: Dutasteride, the dual 5a-reductase inhibitor, inhibits androgen action and promote cell death in the LNCaP prostate cancer cell line. Prostate 58: 130-144, 2004.
28. Huynh H: Induction of apoptosis in rat ventral prostate by finasteride is associated with alteration in MAP kinase pathways and Bcl-2 related family of proteins. Int J Oncol 20: 1297-1303, 2002.
29. Bozec A, Ruffion A, Decaussin M, Andre J, Devonec M, Benahmed M and Mauduit C: Activation of caspases-3, -6, and -9 during finasteride treatment of benign prostatic hyperplasia. J Clin Endocrinol Metab 90: 17-25, 2005.
30. Sutton MT, Yingling M, Vyas A, Atiemo H, Borkowski A, Jacobs SC and Kyprianou N: Finasteride targets prostate vascularity by inducing apoptosis and inhibiting cell adhesion of benign and malignant prostate cells. Prostate 66: 1194-1202, 2006.
31. Tang DG and Porter AT: Target to apoptosis: a hopeful weapon for prostate cancer. Prostate 32: 284-293, 1997.
32. Berchem GJ, Bosseler M, Sugars LY, Voeller HJ, Zeitlin S and Gelmann EP: Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells. Cancer Res 55: 735-738, 1995.
33. Rokhlin OW, Taghiyev AF, Guseva NV, Glover RA, Chumakov PM, Kravchenko JE and Cohen MB: Androgen regulates apoptosis induced by TNFR family ligands via multiple signaling pathways in LNCaP. Oncogene 24: 6773-6784, 2005.
34. Coffey RN, Watson RW, O'Neill AJ, McEleny K and Fitzpatrick JM: Androgen-mediated resistance to apoptosis. Prostate 53: 300-309, 2002.
35. Winter RN, Kramer A, Borkowski A and Kyprianou N: Loss of caspase-1 and caspase-3 protein expression in human prostate cancer. Cancer Res 61: 1227-1232, 2001.
36. Gross A: Bcl-2 proteins: regulators of the mitochondrial apoptotic program. IUBMB Life 52: 231-236, 2001.